APA

de Lima M., Champlin R. E., Thall P. F., Wang X., Martin T. G., Cook J. D., McCormick G., Qazilbash M., Kebriaei P., Couriel D., Shpall E. J., Khouri I., Anderlini P., Hosing C., Chan K. W., Andersson B. S., Patah P. A., Caldera Z., Jabbour E. & Giralt S. (20080326). Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. : Leukemia.

Chicago

de Lima M, Champlin R E, Thall P F, Wang X, Martin T G, Cook J D, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall E J, Khouri I, Anderlini P, Hosing C, Chan K W, Andersson B S, Patah P A, Caldera Z, Jabbour E and Giralt S. 20080326. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. : Leukemia.

Harvard

de Lima M., Champlin R. E., Thall P. F., Wang X., Martin T. G., Cook J. D., McCormick G., Qazilbash M., Kebriaei P., Couriel D., Shpall E. J., Khouri I., Anderlini P., Hosing C., Chan K. W., Andersson B. S., Patah P. A., Caldera Z., Jabbour E. and Giralt S. (20080326). Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. : Leukemia.

MLA

de Lima M, Champlin R E, Thall P F, Wang X, Martin T G, Cook J D, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall E J, Khouri I, Anderlini P, Hosing C, Chan K W, Andersson B S, Patah P A, Caldera Z, Jabbour E and Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. : Leukemia. 20080326.